A drug licensing pact announced this morning has not one but two hot trends in drug deals these days: Japanese Pharma players making deals with U.S. companies, and big drug makers lining up to invest in biotech shops developing RNA-based drugs.
In today’s deal, Takeda will pay Alnylam $100 million upfront, plus another $50 million in [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment